# A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

> **NCT01325415** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 45 (actual)

## Conditions studied

- Amount of NKTR-118 in Blood
- Variation in the Heart's Electrical Cycle

## Interventions

- **DRUG:** NKTR-118
- **DRUG:** moxifloxacin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01325415
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01325415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01325415, "A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01325415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*